Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Csizmar, Clifford M. [1 ]
Saliba, Antoine N. [1 ]
Peterson, Kevin L. [2 ]
Meng, Xue Wei [2 ]
Smith, B. Douglas [3 ]
Ghiaur, Gabriel [4 ]
Patnaik, Mrinal M. [1 ]
Kaufmann, Scott H. [5 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, Div Hematol Malignancies, Baltimore, MD USA
[5] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208583
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5782 / 5783
页数：2
相关论文
共 50 条
  • [21] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
    Kong, Jinyu
    Chen, Nan
    Li, Mengyun
    Zhang, Jian
    Wu, Xiaoxia
    Zong, Lihong
    Wu, Depei
    Song, Baoquan
    Qiu, Huiying
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 697 - 699
  • [22] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
    Jinyu Kong
    Nan Chen
    Mengyun Li
    Jian Zhang
    Xiaoxia Wu
    Lihong Zong
    Depei Wu
    Baoquan Song
    Huiying Qiu
    Annals of Hematology, 2022, 101 : 697 - 699
  • [23] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Pillai, Raju
    Shouse, Geoffrey
    Sanchez, James F.
    Mei, Matthew
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) : E45 - E48
  • [24] Immunohistochemistry for p53 Might Lead to Prompter Treatment in TP53-Mutated Acute Myeloid Leukemia
    Boiocchi, Leonardo
    Crabbe, Andrew
    Brunner, Andrew
    Fathi, Amir T.
    Hasserjian, Robert
    Nardi, Valentina
    LABORATORY INVESTIGATION, 2019, 99
  • [25] Immunohistochemistry for p53 Might Lead to Prompter Treatment in TP53-Mutated Acute Myeloid Leukemia
    Boiocchi, Leonardo
    Crabbe, Andrew
    Brunner, Andrew
    Fathi, Amir T.
    Hasserjian, Robert
    Nardi, Valentina
    MODERN PATHOLOGY, 2019, 32
  • [26] Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies.
    Shapiro, Lauren C.
    Mantzaris, Ioannis
    Shastri, Aditi
    Sica, Alejandro R.
    Bachier-Rodriguez, Lizamarie
    Kornblum, Noah
    Gritsman, Kira
    Feldman, Eric Jay
    Verma, Amit K.
    Braunschweig, Ira
    Saunthararajah, Yogen
    Goldfinger, Mendel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19005 - E19005
  • [27] DNA Hypomethylation Is Not Sufficient to Account for Decitabine Mediated Cytotoxicity in TP53-Mutated Myeloid Malignancies
    Baeten, Jeremy T.
    Agashe, Sumedha
    Quinet, Annabel
    Butler, Jamie
    Carter, Amber C.
    Wooldridge, Jack
    Johansson, Kimberly
    Uy, Geoffrey L.
    Vindigni, Alessandro
    Link, Daniel C.
    BLOOD, 2024, 144 : 5783 - 5783
  • [28] TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations
    DiGennaro, Jeremy
    Sallman, David A.
    ACTA HAEMATOLOGICA, 2024, 147 (02) : 176 - 186
  • [29] TP53 mutated acute myeloid leukemia
    Sill, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 257 - 257
  • [30] Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53-Mutated Acute Myeloid Leukemia
    Jamy, Omer H.
    Diebold, Kendall
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Godby, Kelly N.
    Salzman, Donna
    Bhatia, Ravi
    BLOOD, 2022, 140 : 8959 - 8960
12345